Rationale and prospects for novel pneumococcal vaccines

References

• Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, O'Brien KL, Campbell H, Black RE. Global burden of childhood pneumonia and diarrhoea. Lancet 2013; 381(9875):1405-16; PMID:23582727; http://dx.doi.org/10.1016/S0140-6736(13)60222-6
   PubMed Web of Science ®Google Scholar
• O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374(9693):893-902; PMID:19748398; http://dx.doi.org/10.1016/S0140-6736(09)61204-6
   PubMed Web of Science ®Google Scholar
• Davis SM, Deloria-Knoll M, Kassa HT, O'Brien KL. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine 2013; 32(1):133-45; PMID:23684824; http://dx.doi.org/10.1016/j.vaccine.2013.05.005
   PubMed Web of Science ®Google Scholar
• Loo JD, Conklin L, Fleming-Dutra KE, Knoll MD, Park DE, Kirk J, Goldblatt D, O'Brien KL, Whitney CG. Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization. Pediatr Infect Dis J 2014; 33 Suppl 2:S161-71; PMID:24336058; http://dx.doi.org/10.1097/INF.0000000000000084
   PubMedGoogle Scholar
• Harboe ZB, Dalby T, Weinberger DM, Benfield T, Molbak K, Slotved HC, Suppli CH, Konradsen HB, Valentiner-Branth P. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 2014; 59(8):1066-73; PMID:25034421; http://dx.doi.org/10.1093/cid/ciu524
   PubMed Web of Science ®Google Scholar
• Auranen K, Rinta-Kokko H, Goldblatt D, Nohynek H, O'Brien KL, Satzke C, Simell B, Tanskanen A, Käyhty H. Colonisation endpoints in Streptococcus pneumoniae vaccine trials. Vaccine 2013; 32(1):153-8; PMID:24016803; http://dx.doi.org/10.1016/j.vaccine.2013.08.061
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Ramakrishnan M, O'Brien K. Using the impact of pneumococcal vaccines on nasopharyngeal carriage to aid licensing and vaccine implementation; a PneumoCarr meeting report March 27-28, 2012, Geneva. Vaccine 2013; 32(1):146-52; PMID:23933374; http://dx.doi.org/10.1016/j.vaccine.2013.06.040
   PubMed Web of Science ®Google Scholar
• Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, Levine OS, Whitney CG, O'Brien KL, Moore MR. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med 2013; 10(9):e1001517; http://dx.doi.org/10.1371/journal.pmed.1001517
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infectious Dis 2011; 11(10):760-8; http://dx.doi.org/10.1016/S1473-3099(11)70090-1
   PubMed Web of Science ®Google Scholar
• Tocheva AS, Jefferies JM, Christodoulides M, Faust SN, Clarke SC. Distribution of carried pneumococcal clones in UK children following the introduction of the 7-valent pneumococcal conjugate vaccine: a 3-year cross-sectional population based analysis. Vaccine 2013; 31(31):3187-90; PMID:23680442; http://dx.doi.org/10.1016/j.vaccine.2013.04.075
   PubMed Web of Science ®Google Scholar
• Tocheva AS, Jefferies JM, Rubery H, Bennett J, Afimeke G, Garland J, Christodoulides M, Faust SN, Clarke SC. Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children. Vaccine 2011; 29(26):4400-4; PMID:21504773; http://dx.doi.org/10.1016/j.vaccine.2011.04.004
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378(9807):1962-73; PMID:21492929; http://dx.doi.org/10.1016/S0140-6736(10)62225-8
   PubMed Web of Science ®Google Scholar
• Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci U S A 1997; 94(12):6571-6; PMID:9177259; http://dx.doi.org/10.1073/pnas.94.12.6571
   PubMed Web of Science ®Google Scholar
• Progress in introduction of pneumococcal conjugate vaccine- worldwide, 2000-2012. MMWR Morb Mortal Wkly Rep 2013 Apr 26: Centers for Disease Control and Prevention (CDC)
   Web of Science ®Google Scholar
• Rapola S, Jantti V, Haikala R, Syrjanen R, Carlone GM, Sampson JS, Briles DE, Paton JC, Takala AK, Kilpi TM, et al. Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis 2000; 182(4):1146-52; PMID:10979911; http://dx.doi.org/10.1086/315822
   PubMed Web of Science ®Google Scholar
• Holmlund E, Quiambao B, Ollgren J, Nohynek H, Kayhty H. Development of natural antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A and pneumolysin in Filipino pregnant women and their infants in relation to pneumococcal carriage. Vaccine 2006; 24(1):57-65; PMID:16115703; http://dx.doi.org/10.1016/j.vaccine.2005.07.055
   PubMed Web of Science ®Google Scholar
• Laine C, Mwangi T, Thompson CM, Obiero J, Lipsitch M, Scott JA. Age-specific immunoglobulin g (IgG) and IgA to pneumococcal protein antigens in a population in coastal kenya. Infect Immun 2004; 72(6):3331-5; PMID:15155637; http://dx.doi.org/10.1128/IAI.72.6.3331-3335.2004
   PubMed Web of Science ®Google Scholar
• Anderson P. Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197. Infect Immun 1983; 39(1):233-8; PMID:6600444
   PubMed Web of Science ®Google Scholar
• Anderson P, Pichichero ME, Insel RA. Immunization of 2-month-old infants with protein-coupled oligosaccharides derived from the capsule of Haemophilus influenzae type b. J Pediatr 1985; 107(3):346-51; PMID:3875705; http://dx.doi.org/10.1016/S0022-3476(85)80504-7
   PubMed Web of Science ®Google Scholar
• Anderson P, Pichichero ME, Insel RA. Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197. J Clin Invest 1985; 76(1):52-9; PMID:3874882; http://dx.doi.org/10.1172/JCI111976
   PubMed Web of Science ®Google Scholar
• Anderson PW, Pichichero ME, Insel RA, Betts R, Eby R, Smith DH. Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infant. J Immunol 1986; 137(4):1181-6; PMID:3016088
   PubMed Web of Science ®Google Scholar
• Jakobsen H, Hannesdottir S, Bjarnarson SP, Schulz D, Trannoy E, Siegrist CA, Jonsdottir I. Early life T cell responses to pneumococcal conjugates increase with age and determine the polysaccharide-specific antibody response and protective efficacy. Eur J Immunol 2006; 36(2):287-95; PMID:16385627; http://dx.doi.org/10.1002/eji.200535102
   PubMed Web of Science ®Google Scholar
• Clarke ET, Williams NA, Findlow J, Borrow R, Heyderman RS, Finn A. Polysaccharide-specific memory B cells generated by conjugate vaccines in humans conform to the CD27+IgG+ isotype-switched memory B Cell phenotype and require contact-dependent signals from bystander T cells activated by bacterial proteins to differentiate into plasma cells. J Immunol 2013; 191(12):6071-83; PMID:24227777; http://dx.doi.org/10.4049/jimmunol.1203254
   PubMed Web of Science ®Google Scholar
• Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, Santosham M, Klugman KP, Madhi SA, Paradiso P, Kohberger R. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007; 25(19):3816-26; PMID:17368878; http://dx.doi.org/10.1016/j.vaccine.2007.01.119
   PubMed Web of Science ®Google Scholar
• Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, Keyserling HL, Carlone GM. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997; 4(4):415-22; PMID:9220157
   PubMedGoogle Scholar
• Juergens C, Patterson S, Trammel J, Greenberg D, Givon-Lavi N, Cooper D, Gurtman A, Gruber WC, Scott DA, Dagan R. Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonization. Clin Vaccine Immunol 2014; 21(9):1277-81; PMID:24990907; http://dx.doi.org/10.1128/CVI.00172-14
   PubMed Web of Science ®Google Scholar
• Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis 2013; 57(7):952-62; PMID:23804191; http://dx.doi.org/10.1093/cid/cit428
   PubMed Web of Science ®Google Scholar
• Austrian R. Pneumococcal infections. In: Germanier R, editor. Bacterial Vaccines. Orlando FL: Academic Press; 1984. p. 257-88
   Google Scholar
• Lipsitch M, Whitney CG, Zell E, Kaijalainen T, Dagan R, Malley R. Age-specific incidence of invasive pneumococcal disease by serotype: Are anticapsular antibodies the primary mechanism of protection against invasive disease? PLoS Med 2005; 2(1):e15; PMID:15696204; http://dx.doi.org/10.1371/journal.pmed.0020015
   PubMed Web of Science ®Google Scholar
• Croucher NJ, Chewapreecha C, Hanage WP, Harris SR, McGee L, van der Linden M, Song JH, Ko KS, de Lencastre H, Turner C, et al. Evidence for soft selective sweeps in the evolution of pneumococcal multidrug resistance and vaccine escape. Genome Biol Evol 2014; 6(7):1589-602; PMID:24916661; http://dx.doi.org/10.1093/gbe/evu120
   PubMed Web of Science ®Google Scholar
• Croucher NJ, Harris SR, Fraser C, Quail MA, Burton J, van der Linden M, McGee L, von Gottberg A, Song JH, Ko KS. Rapid pneumococcal evolution in response to clinical interventions. Science 2011; 331(6016):430-4; PMID:21273480; http://dx.doi.org/10.1126/science.1198545
   PubMed Web of Science ®Google Scholar
• Gaschignard J, Levy C, Chrabieh M, Boisson B, Bost-Bru C, Dauger S, Dubos F, Durand P, Gaudelus J, Gendrel D, et al. Invasive pneumococcal disease in children can reveal a primary immunodeficiency. Clin Infect Dis 2014; 59(2):244-51; http://dx.doi.org/10.1093/cid/ciu274
   PubMed Web of Science ®Google Scholar
• Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001; 32(5):794-800; PMID:11229848; http://dx.doi.org/10.1086/319218
   PubMed Web of Science ®Google Scholar
• Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A, Käyhty H, Karma P, Kohberger R, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344(6):403-9; PMID:11172176; http://dx.doi.org/10.1056/NEJM200102083440602
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19(3):187-95
   PubMed Web of Science ®Google Scholar
• Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreno RA, Nohynek H, Riley ID, Makela H. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009(4):CD004977; PMID:19821336
   PubMed Web of Science ®Google Scholar
• Lucero MG, Nohynek H, Williams G, Tallo V, Simoes EA, Lupisan S, Sanvictores D, Forsyth S, Puumalainen T, Ugpo J, et al. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. Pediatr Infect Dis J 2009; 28(6):455-62; PMID:19483514; http://dx.doi.org/10.1097/INF.0b013e31819637af
   PubMed Web of Science ®Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372(12):1114-25; PMID:25785969; http://dx.doi.org/10.1056/NEJMoa1408544
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Bruhn CA, Shapiro ED. Vaccine against Pneumococcal Pneumonia in Adults. N Engl J Med 2015; 373(1):92; PMID:26132955
   PubMed Web of Science ®Google Scholar
• Swartz AW. Vaccine against Pneumococcal Pneumonia in Adults. N Engl J Med 2015; 373(1):91-2; PMID:26132953; http://dx.doi.org/10.1056/NEJMc1505366
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Shapiro ED. Pneumococcal conjugate vaccines for adults: reasons for optimism and for caution. Hum Vaccin Immunother 2014; 10(5):1334-6; PMID:24763136; http://dx.doi.org/10.4161/hv.28962
   PubMed Web of Science ®Google Scholar
• Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003; 22(1):10-6; PMID:12544402; http://dx.doi.org/10.1097/00006454-200301000-00006
   PubMed Web of Science ®Google Scholar
• Kilpi T, Ahman H, Jokinen J, Lankinen KS, Palmu A, Savolainen H, Grönholm M, Leinonen M, Hovi T, Eskola J, et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis 2003; 37(9):1155-64; PMID:14557958; http://dx.doi.org/10.1086/378744
   PubMed Web of Science ®Google Scholar
• Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006; 367(9512):740-8; PMID:16517274; http://dx.doi.org/10.1016/S0140-6736(06)68304-9
   PubMed Web of Science ®Google Scholar
• Rapola S, Kilpi T, Lahdenkari M, Makela PH, Kayhty H. Antibody response to the pneumococcal proteins pneumococcal surface adhesin A and pneumolysin in children with acute otitis media. Pediatr Infect Dis J 2001; 20(5):482-7; PMID:11368104; http://dx.doi.org/10.1097/00006454-200105000-00003
   PubMed Web of Science ®Google Scholar
• Xu Q, Casey JR, Pichichero ME. Higher levels of mucosal antibody to pneumococcal vaccine candidate proteins are associated with reduced acute otitis media caused by Streptococcus pneumoniae in young children. Mucosal Immunol 2015; 8(5):1110-7: e1-8
   PubMed Web of Science ®Google Scholar
• Chandesris MO, Melki I, Natividad A, Puel A, Fieschi C, Yun L, Thumerelle C, Oksenhendler E, Boutboul D, Thomas C, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore) 2012; 91(4):e1-19; PMID:22751495; http://dx.doi.org/10.1097/MD.0b013e31825f95b9
   PubMed Web of Science ®Google Scholar
• Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, Kanno Y, Spalding C, Elloumi HZ, Paulson ML, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008; 452(7188):773-6; PMID:18337720; http://dx.doi.org/10.1038/nature06764
   PubMed Web of Science ®Google Scholar
• Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B, Fulcher DA, Tangye SG, Cook MC. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 2008; 205(7):1551-7; http://dx.doi.org/10.1084/jem.20080218
   PubMed Web of Science ®Google Scholar
• Khader SA, Gaffen SL, Kolls JK. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol 2009; 2(5):403-11; http://dx.doi.org/10.1038/mi.2009.100
   PubMed Web of Science ®Google Scholar
• Kolls JK, Khader SA. The role of Th17 cytokines in primary mucosal immunity. Cytokine Growth Factor Rev 2010; 21(6):443-8; PMID:21095154; http://dx.doi.org/10.1016/j.cytogfr.2010.11.002
   PubMed Web of Science ®Google Scholar
• Khan MN, Pichichero ME. The host immune dynamics of pneumococcal colonization: implications for novel vaccine development. Hum Vaccin Immunother 2014; 10(12):3688-99; PMID:25668673; http://dx.doi.org/10.4161/21645515.2014.979631
   PubMed Web of Science ®Google Scholar
• Ferreira DM, Neill DR, Bangert M, Gritzfeld JF, Green N, Wright AK, Pennington SH, Bricio-Moreno L, Moreno AT, Miyaji EN, et al. Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. Am J Respir Crit Care Med 2013; 187(8):855-64; PMID:23370916; http://dx.doi.org/10.1164/rccm.201212-2277OC
   PubMed Web of Science ®Google Scholar
• Wright AK, Ferreira DM, Gritzfeld JF, Wright AD, Armitage K, Jambo KC, Bate E, El Batrawy S, Collins A, Gordon F. Human nasal challenge with Streptococcus pneumoniae is immunising in the absence of carriage. PLoS Pathog 2012; 8(4):e1002622; PMID:22496648; http://dx.doi.org/10.1371/journal.ppat.1002622
   PubMed Web of Science ®Google Scholar
• McCool TL, Weiser JN. Limited Role of Antibody in Clearance of Streptococcus pneumoniae in a Murine Model of Colonization. Infect Immun 2004; 72(10):5807-13; PMID:15385481; http://dx.doi.org/10.1128/IAI.72.10.5807-5813.2004
   PubMed Web of Science ®Google Scholar
• van Rossum AM, Lysenko ES, Weiser JN. Host and bacterial factors contributing to the clearance of colonization by Streptococcus pneumoniae in a murine model. Infect Immun 2005; 73(11):7718-26; PMID:16239576; http://dx.doi.org/10.1128/IAI.73.11.7718-7726.2005
   PubMed Web of Science ®Google Scholar
• Lu YJ, Gross J, Bogaert D, Finn A, Bagrade L, Zhang Q, Kolls JK, Srivastava A, Lundgren A, Forte S, et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog. 2008; 4(9):e1000159; PMID:18802458; http://dx.doi.org/10.1371/journal.ppat.1000159
   PubMed Web of Science ®Google Scholar
• Trzcinski K, Thompson CM, Srivastava A, Basset A, Malley R, Lipsitch M. Protection against Nasopharyngeal Colonization by Streptococcus pneumoniae is Mediated by Antigen-Specific CD4+ T Cells. Infect Immun 2008; 76(6):2678-84; PMID:18391006; http://dx.doi.org/10.1128/IAI.00141-08
   PubMed Web of Science ®Google Scholar
• Zhang Z, Clarke TB, Weiser JN. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 2009; 119(7):1899-909; PMID:19509469
   PubMed Web of Science ®Google Scholar
• Lu YJ, Skovsted IC, Thompson CM, Anderson PW, Malley R. Mechanisms in the serotype-independent pneumococcal immunity induced in mice by intranasal vaccination with the cell wall polysaccharide. Microb Pathog 2009; 47(3):177-82; PMID:19577628; http://dx.doi.org/10.1016/j.micpath.2009.06.008
   PubMed Web of Science ®Google Scholar
• Moffitt KL, Gierahn TM, Lu YJ, Gouveia P, Alderson M, Flechtner JB, Higgins DE, Malley R. T(H)17-Based Vaccine Design for Prevention of Streptococcus pneumoniae Colonization. Cell Host Microbe 2011; 9(2):158-65; PMID:21320698; http://dx.doi.org/10.1016/j.chom.2011.01.007
   PubMed Web of Science ®Google Scholar
• Feldman C, Anderson R. Review: current and new generation pneumococcal vaccines. J Infect 2014; 69(4):309-25; PMID:24968238; http://dx.doi.org/10.1016/j.jinf.2014.06.006
   PubMed Web of Science ®Google Scholar
• Moffitt KL, Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol 2011; 23(3):407-13; PMID:21514128; http://dx.doi.org/10.1016/j.coi.2011.04.002
   PubMed Web of Science ®Google Scholar
• Miyaji EN, Oliveira ML, Carvalho E, Ho PL. Serotype-independent pneumococcal vaccines. Cell Mol Life Sci 2013; 70(18):3303-26; PMID:23269437; http://dx.doi.org/10.1007/s00018-012-1234-8
   PubMed Web of Science ®Google Scholar
• Darrieux M, Goulart C, Briles D, Leite LC. Current status and perspectives on protein-based pneumococcal vaccines. Crit Rev Microbiol 2015; 41(2):190-200; PMID:23895377; http://dx.doi.org/10.3109/1040841X.2013.813902
   PubMed Web of Science ®Google Scholar
• Ren B, Li J, Genschmer K, Hollingshead SK, Briles DE. The absence of PspA or presence of antibody to PspA facilitates the complement-dependent phagocytosis of pneumococci in vitro. Clin Vaccine Immunol 2012; 19(10):1574-82; PMID:22855389; http://dx.doi.org/10.1128/CVI.00393-12
   PubMed Web of Science ®Google Scholar
• Ren B, Szalai AJ, Hollingshead SK, Briles DE. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun 2004; 72(1):114-22; PMID:14688088; http://dx.doi.org/10.1128/IAI.72.1.114-122.2004
   PubMed Web of Science ®Google Scholar
• Ren B, Szalai AJ, Thomas O, Hollingshead SK, Briles DE. Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect Immun 2003; 71(1):75-85; PMID:12496151; http://dx.doi.org/10.1128/IAI.71.1.75-85.2003
   PubMed Web of Science ®Google Scholar
• Wu HY, Nahm MH, Guo Y, Russell MW, Briles DE. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 1997; 175(4):839-46; PMID:9086139; http://dx.doi.org/10.1086/513980
   PubMed Web of Science ®Google Scholar
• McCool TL, Cate TR, Tuomanen EI, Adrian P, Mitchell TJ, Weiser JN. Serum immunoglobulin G response to candidate vaccine antigens during experimental human pneumococcal colonization. Infect Immun 2003; 71(10):5724-32; PMID:14500493; http://dx.doi.org/10.1128/IAI.71.10.5724-5732.2003
   PubMed Web of Science ®Google Scholar
• Nabors GS, Braun PA, Herrmann DJ, Heise ML, Pyle DJ, Gravenstein S, Schilling M, Ferguson LM, Hollingshead SK, Briles DE, et al. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 2000; 18(17):1743-54; PMID:10699322; http://dx.doi.org/10.1016/S0264-410X(99)00530-7
   PubMed Web of Science ®Google Scholar
• Briles DE, Hollingshead SK, King J, Swift A, Braun PA, Park MK, Ferguson LM, Nahm MH, Nabors GS. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 2000; 182(6):1694-701; PMID:11069242; http://dx.doi.org/10.1086/317602
   PubMed Web of Science ®Google Scholar
• Ginsburg AS, Nahm MH, Khambaty FM, Alderson MR. Issues and challenges in the development of pneumococcal protein vaccines. Expert Rev Vaccines 2012; 11(3):279-85; PMID:22380821; http://dx.doi.org/10.1586/erv.12.5
   PubMed Web of Science ®Google Scholar
• Alexander JE, Lock RA, Peeters CC, Poolman JT, Andrew PW, Mitchell TJ, Hansman D, Paton JC. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun 1994; 62(12):5683-8; PMID:7960154
   PubMed Web of Science ®Google Scholar
• Francis JP, Richmond PC, Pomat WS, Michael A, Keno H, Phuanukoonnon S, Nelson JB, Whinnen M, Heinrich T, Smith F, et al. Maternal antibodies to pneumolysin but not to pneumococcal surface protein A delay early pneumococcal carriage in high-risk Papua New Guinean infants. Clin Vaccine Immunol 2009; 16(11):1633-8; http://dx.doi.org/10.1128/CVI.00247-09
   PubMed Web of Science ®Google Scholar
• Kaur R, Surendran N, Ochs M, Pichichero ME. Human antibodies to PhtD, PcpA, and Ply reduce adherence to human lung epithelial cells and murine nasopharyngeal colonization by Streptococcus pneumoniae. Infect Immun 2014; 82(12):5069-75; PMID:25245804; http://dx.doi.org/10.1128/IAI.02124-14
   PubMed Web of Science ®Google Scholar
• Walker JA, Allen RL, Falmagne P, Johnson MK, Boulnois GJ. Molecular cloning, characterization, and complete nucleotide sequence of the gene for pneumolysin, the sulfhydryl-activated toxin of Streptococcus pneumoniae. Infect Immun 1987; 55(5):1184-9; PMID:3552992
   PubMed Web of Science ®Google Scholar
• Kamtchoua T, Bologa M, Hopfer R, Neveu D, Hu B, Sheng X, Corde N, Pouzet C, Zimmermann G, Gurunathan S. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults. Vaccine. 2013; 31(2):327-33; PMID:23153437; http://dx.doi.org/10.1016/j.vaccine.2012.11.005
   PubMed Web of Science ®Google Scholar
• Wizemann TM, Heinrichs JH, Adamou JE, Erwin AL, Kunsch C, Choi GH, Barash SC, Rosen CA, Masure HR, Tuomanen E, et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun 2001; 69(3):1593-8; PMID:11179332; http://dx.doi.org/10.1128/IAI.69.3.1593-1598.2001
   PubMed Web of Science ®Google Scholar
• Adamou JE, Heinrichs JH, Erwin AL, Walsh W, Gayle T, Dormitzer M, Dagan R, Brewah YA, Barren P, Lathigra R, et al. Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun 2001; 69(2):949-58; PMID:11159990; http://dx.doi.org/10.1128/IAI.69.2.949-958.2001
   PubMed Web of Science ®Google Scholar
• Godfroid F, Hermand P, Verlant V, Denoel P, Poolman JT. Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect Immun 2011; 79(1):238-45; PMID:20956575; http://dx.doi.org/10.1128/IAI.00378-10
   PubMed Web of Science ®Google Scholar
• Khan MN, Pichichero ME. Vaccine candidates PhtD and PhtE of Streptococcus pneumoniae are adhesins that elicit functional antibodies in humans. Vaccine 2012; 30(18):2900-7; PMID:22349524; http://dx.doi.org/10.1016/j.vaccine.2012.02.023
   PubMed Web of Science ®Google Scholar
• Khan MN, Pichichero ME. CD4 T cell memory and antibody responses directed against the pneumococcal histidine triad proteins PhtD and PhtE following nasopharyngeal colonization and immunization and their role in protection against pneumococcal colonization in mice. Infect Immun 2013; 81(10):3781-92; PMID:23897609; http://dx.doi.org/10.1128/IAI.00313-13
   PubMed Web of Science ®Google Scholar
• Odutola A, Ota MO, Antonia M, Ogundarw OE, Owiafe P, Worwui A, Greenwood B, Alderson M, Traskine M, Dobbelaere K, et al, editor. Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2-4 years: phase II randomized study. ISPPD-Abstract 0407 2014; Hyderabad, India
   Google Scholar
• Prymula R, Szenborn L, Silfverdal SA, Wysocki J, Albrecht P, Francois N, Gardev A, Borys D, editor. Immunogenicity of primary vaccination with an investigational protein-based pneumococcal vaccine in infants in Europe: a phase II randomized trial. ISPPD-Abstract 0551 2014; Hyderabad, India
   Google Scholar
• Chang L, Brooks WA, deBruyn G, Bologa M, Hopfer R, Kriby D¸ Sheng X, Neveu D, Menezes J, Ochs M, et al, editor. A multi-component pneumococcal protein vaccine is safe and immunogenic in a phase I randomized, placebo-controlled study. ISPPD- Abstract 0542 2014; Hyderabad, India
   Google Scholar
• Khan MN, Sharma SK, Filkins LM, Pichichero ME. PcpA of Streptococcus pneumoniae mediates adherence to nasopharyngeal and lung epithelial cells and elicits functional antibodies in humans. Microbes Infect 2012; 14(12):1102-10; PMID:22796387; http://dx.doi.org/10.1016/j.micinf.2012.06.007
   PubMed Web of Science ®Google Scholar
• Glover DT, Hollingshead SK, Briles DE. Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis. Infect Immun 2008; 76(6):2767-76; PMID:18391008; http://dx.doi.org/10.1128/IAI.01126-07
   PubMed Web of Science ®Google Scholar
• Bologa M, Kamtchoua T, Hopfer R, Sheng X, Hicks B, Bixler G, Hou V, Pehlic V, Yuan T, Gurunathan S. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine. Vaccine 2012; 30(52):7461-8; PMID:23123106; http://dx.doi.org/10.1016/j.vaccine.2012.10.076
   PubMed Web of Science ®Google Scholar
• Talkington DF, Brown BG, Tharpe JA, Koenig A, Russell H. Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (PsaA). Microb Pathog 1996; 21(1):17-22; PMID:8827703; http://dx.doi.org/10.1006/mpat.1996.0038
   PubMed Web of Science ®Google Scholar
• Whaley MJ, Sampson JS, Johnson SE, Rajam G, Stinson-Parks A, Holder P, Mauro E, Romero-Steiner S, Carlone GM, Ades EW. Concomitant administration of recombinant PsaA and PCV7 reduces Streptococcus pneumoniae serotype 19A colonization in a murine model. Vaccine 2010; 28(18):3071-5; PMID:20206671; http://dx.doi.org/10.1016/j.vaccine.2010.02.086
   PubMed Web of Science ®Google Scholar
• Briles DE, Ades E, Paton JC, Sampson JS, Carlone GM, Huebner RC, Virolainen A, Swiatlo E, Hollingshead SK. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 2000; 68(2):796-800; PMID:10639448; http://dx.doi.org/10.1128/IAI.68.2.796-800.2000
   PubMed Web of Science ®Google Scholar
• Giefing C, Meinke AL, Hanner M, Henics T, Bui MD, Gelbmann D, Lundberg U, Senn BM, Schunn M, Habel A, et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med 2008; 205(1):117-31; PMID:18166586; http://dx.doi.org/10.1084/jem.20071168
   PubMed Web of Science ®Google Scholar
• Schmid P, Selak S, Keller M, Luhan B, Magyarics Z, Seidel S, Schlick P, Reinisch C, Lingnau K, Nagy E, et al. Th17/Th1 biased immunity to the pneumococcal proteins PcsB, StkP and PsaA in adults of different age. Vaccine 2011; 29(23):3982-9; PMID:21481328; http://dx.doi.org/10.1016/j.vaccine.2011.03.081
   PubMed Web of Science ®Google Scholar
• Nagy E, editor. IC47, a novel protein-based pneumococcal vaccine: from bench to the clinic. ISPPD- Abstract 031 2010; Tel Aviv, Israel
   Google Scholar
• Li Y, Gierahn T, Thompson CM, Trzcinski K, Ford CB, Croucher N, Gouveia P, Flechtner JB, Malley R, Lipsitch M, et al. Distinct effects on diversifying selection by two mechanisms of immunity against Streptococcus pneumoniae. PLoS Pathog 2012; 8(11):e1002989; PMID:23144610; http://dx.doi.org/10.1371/journal.ppat.1002989
   PubMed Web of Science ®Google Scholar
• Moffitt K, Skoberne M, Howard A, Gavrilescu LC, Gierahn T, Munzer S, Dixit B, Giannasca P, Flechtner JB, Malley R. Toll-like receptor 2-dependent protection against pneumococcal carriage by immunization with lipidated pneumococcal proteins. Infect Immun 2014; 82(5):2079-86; PMID:24614661; http://dx.doi.org/10.1128/IAI.01632-13
   PubMed Web of Science ®Google Scholar
• Skoberne M MM, Morris A, Hopson K, Chan J, O'Toole M, Velez D, Siddall N, Hart M, Cooney M, Flechtner JB, et al, editor. Safety and immunogenicity of a novel lipidated protein subunit Streptococcus pneumoniae vaccine. Int Conference Antimicrobial Agents Chemotherapy 2014; Washington, DC
   Google Scholar
• Xin W, Li Y, Mo H, Roland KL, Curtiss R, 3rd. PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae. Infect Immun 2009; 77(10):4518-28; PMID:19687204; http://dx.doi.org/10.1128/IAI.00486-09
   PubMed Web of Science ®Google Scholar
• Frey SE, Lottenbach KR, Hill H, Blevins TP, Yu Y, Zhang Y, Brenneman KE, Kelly-Aehle SM, McDonald C, Jansen A, et al. A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA. Vaccine 2013; 31(42):4874-80; PMID:23916987; http://dx.doi.org/10.1016/j.vaccine.2013.07.049
   PubMed Web of Science ®Google Scholar
• Makela PH BJ. History of pneumococcal immunization. Siber GR KK, Makela PH. Washington, DC.: ASM Press; 2008
   Google Scholar
• Lu YJ, Leite L, Goncalves VM, Dias Wde O, Liberman C, Fratelli F, Alderson M, Tate A, Maisonneuve JF, Robertson G, et al. GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine 2010; 28(47):7468-75; PMID:20858450; http://dx.doi.org/10.1016/j.vaccine.2010.09.031
   PubMed Web of Science ®Google Scholar
• Lu YJ, Yadav P, Clements JD, Forte S, Srivastava A, Thompson CM, Seid R, Look J, Alderson M, Tate A, et al. Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol 2010; 17(6):1005-12; PMID:20427625; http://dx.doi.org/10.1128/CVI.00036-10
   PubMed Web of Science ®Google Scholar
• Alderson M, Malley R, Anderson P, Thompson C, Morrison R, Briles D, King J, Goldblatt D, Green N, Hural J, et al, editor. A phase 1 study to assess the safety, tolerability and immunogenicity of inactivated non-encapsualted Streptococcus pneumoniae whole cell vaccine. ISPPD- Abstract 0121 2014; Hyderabad, India
   Google Scholar
• Briles D, King J, Hale Y, Malley R, Anderson P, Keech C, Tate A, Maisonneuve J, Alderson M. editor. Immune sera from adults immunized with killed whole cell nonencapsulated vaccine protects mice from fatal infection with type 3 pneumococci. ISPPD- Abstract 0122 2104; Hyderabad, India
   Google Scholar